Skip to Content
  • Previous Rank
    78
  • Revenues ($M)
    $42,294.0
  • Revenue Percent Change
    5.4%
  • Profits ($M)
    $6,220.0
  • Profits Percent Change
    159.8%
  • Assets ($M)
    $82,637.0
  • Employees
    69,000

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Websitehttp://www.merck.com
Years on Fortune 500 List65
Employees69,000

Merck Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$42,294.05.4%
Profits ($M)$6,220.0159.8%
Assets ($M)$82,637.0-
Total Stockholder Equity ($M)$26,701.0-

Profit Ratios

Profit as % of Revenues14.7%
Profits as % of Assets7.5%
Profits as % of Stockholder Equity23.3%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)2.32
EPS % Change (from 2017)166.7%
EPS % Change (5 year annual rate)9.6%
EPS % Change (10 year annual rate)-4.4%

Total Return

Total Return to Investors (2018)40.2%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)13.8%